This article is more than 5 years old. Information may no longer be current.
AAOS releases new position statement on use of emerging biologic therapies
Click Here to Manage Email Alerts
The American Academy of Orthopaedic Surgeons Board of Directors have approved a new “Use of Emerging Biologic Therapies” position statement highlights the importance of understanding the risks and benefits of stem cell and other biologic treatments for musculoskeletal joint conditions.
Unlike many traditional orthopedic treatments, emerging biologic therapies may not have safety and efficacy profiles, according to the statement. Since patient education is needed for informed consent, the statement includes two additional AAOS guidelines—“Orthopaedic Surgical Consent” and “Standards of Professionalism”—that reinforce the orthopedic surgeon’s role of fully informing patients of the risks and benefits of various treatments, securing patient consent before continuing with a particular modality.
The statement also highlights the importance of the support and participation of orthopedic surgeons and their organizations or facilities in orthopedic registries and other data collection systems to improve patient care and safety.
“While gaining in popularity, and providing relief for some patients, biologic treatments may lack the demonstrated safety and efficacy of many traditional orthopedic therapeutics,” J. Tracy Watson, MD, chair of the AAOS Biologics Committee, said in a press release. “The Academy wants to make sure that doctors and patients are making informed treatment decisions, based on the most current research and product indications.”
Reference:
https://www.aaos.org/About/Statements/Position/?ssopc=1